RBM5: potential drug target for acute myeloid leukaemia
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
List view / Grid view
News
Changes in CD4+ T cells associated with autoimmune diseases
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Nasal administration of IgA antibodies protects from SARS-CoV-2
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.
Unexpected patterns in DNA mutations identified
Disruptions in TP53 and RB1 are key influencers that cause changes in the risk of mutations across chromosomes.
Blood test developed that reliably detects NEPC
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
CBPUV nanoparticles show excellent anticancer activity
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
Using proteomics to predict long-term disability outcomes in MS
Data from protein analyses, combined with data from patient journals, enabled the discovery of proteins that predict disease progression.
Neurodevelopmental defects seen in mini-brains with ANG mutation
Researchers found that ANG in its mutated form slows stem cell differentiation, resulting in neurodevelopmental defects in adult nerve cells.
Discovery of a previously unknown class of HK-CREs
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.
Advancing the development of CTLA-4 inhibitors
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
Controlling MYC’s hyperactivity with a peptide compound
A novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development.
Delivering a human monoclonal IgG1 antibody to the brain
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.
The loading mechanism of bacteria injectisomes is now understood
Proximity labelling and single-particle tracking demonstrated that effectors in bacteria bind to mobile injectisome components.
Potential of precision diagnostics for gestational diabetes mellitus
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Discovery enables further investigation into new ligases
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.